NYSE: EHC

Encompass Health (EHC) Stock Analysis & Forecast

Nov 13 close

$140.99+0.16 (+0.1%)

Gekko Brief

AI summaryNov 9 close

Encompass Health reached a fresh 52-week high this week, with shares up 9.52% over one week amid continued momentum. The company announced the indefinite closure of Sea Pines Rehabilitation Hospital in Melbourne, Florida, following flood damage from torrential rains on 1-2 November 2026, with all patients evacuated safely and employees accounted for. Separately, analysts covering the stock have maintained an average "Buy" recommendation, and a Form 8-K filing was disclosed on 6 November as standard regulatory reporting.

EHC closed at $141.15, up 2.6%, sitting above both its 50-day average of $125.06 and 200-day average of $111.21, with the shorter average above the longer one. The stock trades near its 52-week high of $143.36, well above its 52-week low of $92.77. The GekkoIndex reading of 45.5 places it in the Neutral zone. Price stands 17.8% above the Gekko Fair Value of $119.87.

The next earnings report is scheduled for 4 February 2027, 86 days out and beyond a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in their respective windows, and one trailblazer holder is noted among institutional categories. Nine covering firms currently rate the stock Buy, with a consensus target of $156.08. Seasonality over the past 5 years shows the next 20 trading days from this point averaging -0.5%, with gains in 3 of those years, a pattern worth noting given the stock's recent strength into a 52-week high.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Encompass Health price vs fair value

$140.99$122.89Nov ’25May ’26Nov ’26
Close $140.99200-day averageGekko Fair Value $122.89

Encompass Health quick facts

Market cap
$13.83B
P/E ratio
22.5
Forward P/E
19.1
EPS, TTM
$6.25
Revenue, TTM
$6.34B
Profit margin
10.2%
Dividend yield
0.55%
Beta
0.67
Volume
502,854 avg 1.21M
1-year return
+22.8%
Typical daily move
±3.1%
Typical 20-day move
±4.9%
50-day average
$126.67
200-day average
$112.14
Next earnings
Feb 4
Shares outstanding
98.12M
52-week range
$92.77$143.90

Encompass Health swing-trade checklist

Encompass Health scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive2 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $140.99 is above the 50-day ($126.67) and 200-day ($112.14) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    49, Neutral

    Reading 49 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    14.7% above

    Price is 14.7% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 81 days

    Next report Feb 4, 2027, 81 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    −0.2% on average

    From this point in the calendar, the next 20 trading days averaged −0.2% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Encompass Health stock chart and price history

Encompass Health closed at $140.99 on Nov 13, 2026, +22.8% over the past year, inside a 52-week range of $92.77 to $143.90.

Close50-day average200-day averageVolume
Encompass Health share price, past year, with 50-day and 200-day moving averages and volume$100$110$120$130DecJan 2026FebMarAprMayJunJulAugSepOctNov140.99

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+10.3%
3 months
+15.6%
6 months
+32.2%
1 year
+22.8%
The full EHC chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open EHC in Gekko

Follow Encompass Health through every session

Put EHC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track EHC in GekkoFree for 7 days. No credit card required.

About Encompass Health

Encompass Health treats patients recovering from major medical events, working with them either inside its own facilities or at their place of residence. It has built recognition for guiding recovery from conditions like stroke, neurological disease, heart and lung ailments, brain and spinal injuries, difficult orthopedic cases, and limb loss, with programs structured for both overnight stays and outpatient visits.

Its business splits into two branches. One centers on rehabilitation for patients needing intensive, supervised recovery after a serious diagnosis. The other, focused mainly on the Southeast and Texas, brings Medicare-certified home health offerings to adult patients, covering skilled nursing, social work support, aide services, and physical, occupational, and speech therapy, plus hospice care that comforts dying patients and their loved ones in a home setting.

The company got its start in 1983 and keeps its headquarters in Birmingham, Alabama. It once operated under the name HealthSouth Corporation, adopting the Encompass Health identity in January 2018. Its stock trades on the NYSE under the ticker EHC.

Listed
NYSE
Sector
Health services
Industry
Medical/Nursing services
Website
encompasshealth.com

Encompass Health GekkoIndex: the smart money zone

Encompass Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 49, in the Neutral zone, up 3.4 points over five sessions.

010049Neutral

Up 3.4 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying40+0.6%+3.0%+5.6%+4.3%
Accumulation133+1.0%+1.6%+3.3%+5.7%
Neutral (current zone)487+0.6%+0.9%+1.3%+4.6%
Distribution41−1.4%−1.0%+0.5%−0.8%
Selling1Too few readings yet

Average EHC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the EHC price, zone by zone.Track EHC in Gekko

Is Encompass Health stock overvalued? Gekko Fair Value

Encompass Health trades 14.7% above Gekko Fair Value of $122.89, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Encompass Health shares are worth, recalculated every trading day.

$122.89

Gekko Fair Value, Nov 14, 2026

14.7% Overvalued

At the end of Aug 2026 the price was 27.9% above the estimate.

Gekko Fair ValueShare price, month end
$123$141Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open EHC in Gekko

Encompass Health insider and Congress trading

No open-market insider purchases were filed for Encompass Health, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for EHC in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every EHC insider filing, plotted on the chart in Gekko.Open EHC in Gekko

Congress trades last 90 days

No trades in EHC were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for EHC, plotted on the chart in Gekko.Open EHC in Gekko

Buybacks

Encompass Health has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$57.90M
As a share of market cap
0.42%
Trailing four quarters
$280.1M

From company filings.

Hedge funds and billionaires quarter ended Dec 31

1of the funds Gekko tracks holds EHC.

1added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Encompass Health earnings: next date and track record

Encompass Health reports on Feb 4, 2027 (81 days away), and beat the EPS estimate in 8 of its last 8 reports.

8 of 8reports beat the EPS estimate
±7.2%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

−8.7%Aug ’24+7.0%Oct ’24−2.3%Feb ’25+12.6%Apr ’25+4.9%Aug ’25−7.5%Oct ’25+10.2%Feb ’26+4.7%Apr ’26

Last earnings call, Apr 30, 2026 AI summary

What they said
Encompass Health reported Q1 2026 revenue growth of 9% and adjusted EBITDA growth of 11.2%, prompting a guidance raise for full year 2026. Clinical quality metrics improved year-over-year, with discharge community rate reaching 84.5%. RN turnover hit a historic low of 17.8%, driving a 9.4% decline in premium labor spend. The company opened one new 49-bed hospital and added 44 beds, with 7 more hospitals and 340 beds planned for the remainder of 2026.
Guidance
Management raised full-year 2026 guidance based on Q1 outperformance. Beyond 2026, the pipeline includes 11 announced hospitals with 520 beds, plus at least one small-format hospital planned for 2027.
ReportedEPSSurpriseRevenueSurpriseMove
Apr 30, 2026$1.60
est $1.49
+7.4%$1.59B
est $1.57B
+1.2%+4.7%
Feb 5, 2026$1.46
est $1.30
+12.3%$1.54B
est $1.54B
+0.3%+10.2%
Oct 29, 2025$1.23
est $1.19
+3.4%$1.48B
est $1.54B
−4.1%−7.5%
Aug 4, 2025$1.40
est $1.23
+13.8%$1.46B
est $1.43B
+2.1%+4.9%
Apr 24, 2025$1.37
est $1.19
+15.1%$1.46B
est $1.43B
+2.1%+12.6%
Feb 6, 2025$1.17
est $1.02
+14.7%$1.41B
est $1.38B
+1.7%−2.3%
Oct 28, 2024$1.03
est $0.94
+9.6%$1.35B
est $1.38B
−2.0%+7.0%
Aug 5, 2024$1.11
est $1.01
+9.9%$1.30B
est $1.30B
0.0%−8.7%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Encompass Health stock forecast and analyst price targets

Analysts’ average 12-month price target for Encompass Health is $156.08, +10.7% from the last close, from 9 firms rating the stock in the last 90 days.

$156.08consensus 12-month target, +10.7% from the last close
Low $142High $177
Buy9
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 9 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 2Mizuho SecuritiesBuy, maintained$155+9.9%
Nov 2Leerink PartnersBuy, maintained$177+25.5%
Oct 30UBSBuy, reiterated$165+17.0%
Oct 30TD CowenBuy, maintained$150+6.4%
Oct 30UBSBuy, maintained$165+17.0%
+1.3%average 20-day move after past Neutral readings
−0.2%average move over the next 20 trading days in the last 5 years
±3.1%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Encompass Health seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Encompass Health averaged −0.2% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

+3.0%2021+1.6%2022+3.6%2023−3.0%2024−5.2%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−0.4%3 of 5
Next 10 trading days−1.3%3 of 5
Next 15 trading days−0.1%3 of 5
Next 20 trading days−0.2%3 of 5
Next 30 trading days−0.1%3 of 5

For scale, EHC’s typical 20-trading-day move in either direction is about 4.9%.

Encompass Health market cap and key statistics

Encompass Health’s market cap is $13.83B, with a P/E ratio of 22.5 and revenue of $6.34B over the last twelve months.

Valuation

Market cap
$13.83B
P/E ratio
22.5
Forward P/E
19.1
EPS, TTM
$6.25
Gekko Fair Value
$122.89

Trading

Volume
502,854
Avg volume, 20 days
1.21M
52-week high
$143.90
52-week low
$92.77
Shares outstanding
98.12M

Financials

Revenue, TTM
$6.34B
Profit margin
10.2%
Return on equity
25.1%
Quarterly earnings growth, YoY
+21.6%

Risk and income

Beta
0.67
Typical daily move
±3.1%
Typical 20-day move
±4.9%
Dividend yield
0.55%

Encompass Health stock news this week

Coverage of Encompass Health this week reads neutral: 0 positive, 3 neutral and 0 negative headlines.

News sentiment neutral

Encompass Health peers

Encompass Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LHLabcorp−1.0%Neutral8.5% above
GHGuardant Health−2.8%Accumulation16.4% below
SOLVSolventum0.0%Neutral17.0% below
BTSGBrightSpring Health Services0.0%Neutral11.0% above
ENSGEnsign+0.3%Neutral15.6% above
DVADaVita−0.3%Accumulation25.6% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical/Nursing services

Encompass Health stock FAQ

What is Encompass Health’s market cap?

Encompass Health’s market cap is $13.83B at the Nov 13, 2026 close of $140.99, with 98.12M shares outstanding. The shares trade on a P/E ratio of 22.5.

What is the Encompass Health stock forecast?

The consensus analyst 12-month price target for Encompass Health is $156.08, +10.7% from the last close. Of the 9 firms that rated the stock in the last 90 days, 9 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Encompass Health stock overvalued or undervalued?

On Gekko’s estimate Encompass Health is overvalued: the Nov 13, 2026 close of $140.99 is 14.7% above Gekko Fair Value of $122.89. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Encompass Health report earnings next?

Encompass Health is expected to report on Feb 4, 2027 (81 days away). Analysts expect earnings of $1.60 per share on revenue of $1.68B. Encompass Health beat the earnings estimate in 8 of its last 8 reports, moving 7.2% on average across the report.

What is Encompass Health’s 52-week high and low?

Encompass Health’s 52-week high is $143.90 and its 52-week low is $92.77; it closed at $140.99 on Nov 13, 2026, +22.8% over the past year.

Is Encompass Health stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Encompass Health the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.